Primary: Circular production processes and ethanol/water reuse at API sites Internal reuse of ethanol at the two largest API production sites reduces use of new ethanol by ~90%. At Kalundborg, ethanol waste and yeast slurry are turned into energy and fertiliser via the Kalundborg Symbiosis. District cooling project (operational 2026) expected to save ~400,000 m³ water/year. Wastewater treatment capacity at Kalundborg being doubled by 2026.
▾ expand
New scope 3 reduction target: 33% by 2033 vs 2024 baseline In 2024, Novo Nordisk updated its decarbonisation roadmap, setting a new target of 33% absolute scope 3 reduction by 2033 from a 2024 baseline. Covers ~70% of scope 3 in accordance with SBTi provisions, submitted for SBTi validation. Aligned with well-below 2.0°C pathway (not 1.5°C).
▾ expand
Carbon removals up to 10% of baseline emissions to neutralise residual by 2045 Beyond 2033, Novo Nordisk expects to use carbon removals to neutralise residual CO2e emissions of up to 10% of the baseline towards the net zero 2045 target, aligned with SBTi requirements and IPCC guidance. Exploring both nature-based and technology-based solutions for removing and storing GHG. Removals are not used to meet the 2033 scope 3 (-33%) interim target.
▾ expand
Acquired three Catalent fill-finish sites for USD 11.7bn On 18 December 2024, Novo Nordisk acquired three fill-finish sites in US, Belgium and Italy from Novo Holdings A/S (via Catalent acquisition) for USD 11.7bn (DKK 82.1bn). Adds ~3,500 employees and significant manufacturing capacity. Mainly debt-financed via EUR 4.65bn Eurobond issuance.
▾ expand
Plastic footprint reduction target: 30% per patient by 2033 Set new global target to reduce plastic footprint per patient by 30% by 2033, from baseline of 0.35 kg/patient in 2024. Achieved via reusable devices, circular design and less-frequent dosing.
▾ expand
Nature roadmap: halt nature loss by 2033, nature positive by 2045 Formalised a nature roadmap in 2024 with ambition to halt loss of nature in value chain by 2033 and achieve nature-positive status by 2045. Aligned with Kunming-Montreal Biodiversity Framework. Includes deforestation-free paper/cardboard supply chain and regenerative glucose sourcing.
▾ expand
CSRD-aligned Sustainability statement (first year) 2024 is the first year Novo Nordisk's Sustainability statement is prepared under EU Corporate Sustainability Reporting Directive (CSRD)/ESRS, with a double materiality assessment. Significantly expanded disclosure scope.
▾ expand
Limited assurance on Sustainability statement by Deloitte Deloitte provided limited assurance on the Sustainability statement under ISAE 3000 (Revised), covering ESRS compliance and EU Taxonomy disclosures.
▾ expand
CDP A List 2024 - climate disclosure recognition Recognised by CDP among leaders on climate and water disclosure (general release 6 Feb 2025).
▾ expand
Scope 1 and 2 zero CO2e by 2030 target maintained Target of zero scope 1 and 2 (market-based) CO2e emissions by 2030. ~131 ktCO2e of expected reductions identified across scope 1+2 by 2030.
▾ expand
see 7 more events →